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Synthetic studies on the bioactive tetramic acid
JBIR-22 using a late stage Diels–Alder reaction†
A. R. Healy and N. J. Westwood*
A late stage Diels–Alder reaction is used to prepare a mixture of JBIR-22, a natural product from the Equi-
setin family of tetramic acids, and one of its diastereomers. This is achieved in just 8 steps from pyruvate.
The success of the late stage DA approach is discussed in the context of the biosynthesis of JBIR-22 (and
perhaps related natural products).
Introduction
The presence of unsaturated decalin rings in a wide range of
secondary metabolites (Fig. 1) has led to the proposal that
enzyme-catalysed intramolecular Diels–Alder (IMDA) cyclo-
additions are involved in the biosynthesis of this unit.1
Despite the large number of reports, few enzymes have been
discovered which are truly consistent with the label of a
“Diels–Alderase” and there remains controversy in several
cases.2 Key challenges involve demonstrating that an enzyme:
(i) catalyses the cycloaddition reaction and (ii) is unambigu-
ously in control of the observed product stereochemistry.2
Examples where the stereochemical outcome of the DA reac-
tion diﬀers in the presence or absence of the enzyme provide
the most compelling cases for the involvement of a Diels–
Alderase.2b,f However, in several cases the product of a pro-
posed enzyme-catalysed DA reaction would be expected to have
the same stereochemistry whether the reaction is enzyme- or
substrate-controlled (for example see Scheme 1A).
Polyketide or hybrid polyketide-nonribosomal peptide
(PKS-NRP) metabolites isolated from bacterial and fungal
sources are a rich source of biologically active compounds.3
Several of these molecules contain an unsaturated decalin ring
system.2d For example, the HIV-1 integrase inhibitor equisetin
(1) is representative of a family of tetramic acid-based natural
products of this type (Fig. 1). The complex structure of 1 and
its potent biological activity has prompted synthetic and
biosynthetic studies.4 The biosynthesis of equisetin (1) is
proposed to involve an early stage enzyme-catalysed IMDA
reaction similar to that observed in the biosynthesis of the
cholesterol-lowering drug Lovastatin (2) (Fig. 1 and Scheme 1A
and B).4b,5 This is due to similarities in the domain organis-
ation observed for the equisetin (1) PKS-NRP synthase Eqx
compared to the lovastatin (2) megasynthetase, LovB.1a,2b,6
Numerous synthetic studies have shown that the presence
of the C8-methyl stereocentre4d in the DA precursor of 1
(Scheme 1A) directs the production of a major endo adduct
with the same absolute stereochemistry at C11, C2, C3 and C6
as the natural product 1, in the absence of an enzyme.4d–f,7–10
Recent reports on the isolation, biological evaluation and syn-
thesis of additional members of this family have refocused
attention on the DA reaction.11–17 For example, the potent
PAC3 protein–protein interaction inhibitor, JBIR-22 (3) is of
interest in this context as it lacks a C8-stereocentre4d
(Scheme 1C) that could control the formation of the correct
Fig. 1 Examples of natural products that contain an unsaturated decalin
ring system that may be formed by a Diels–Alderase catalysed reaction.
aTo date only the relative stereochemistry of 4 has been reported.
†Electronic supplementary information (ESI) available: UPLC, NMR and all
experimental protocols. See DOI: 10.1039/c5ob01771h
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absolute stereochemistry in the decalin unit. Given all this, it
is possible that an enzyme-controlled DA reaction is involved
in the biosynthesis of JBIR-22 (3).
Determining whether a Diels–Alderase is actually involved
in a biosynthetic sequence to 3 requires extensive studies
beyond the scope of this report. However, an interesting ques-
tion relating to the timing of the required DA reaction can be
addressed through synthetic studies with the issue being
whether this reaction can occur early (Scheme 1C, Route A as
for lovastatin (2)) or late (Scheme 1C, Route B). Whilst current
opinion sides with an early DA reaction, the feasibility of a late
stage DA reaction is understudied.1a,d,2f A recent disclosure
involving the structurally-related HIV inhibitor Sch210972 (4)
(Fig. 1 & Scheme S1†) supports the feasibility of a late stage
DA.18,2f Here we provide evidence that whilst a spontaneous late
stage DA reaction does not lead to JBIR-22 (3) in the lab, with a
suitable catalyst, this late stage DA reaction is possible and in
the absence of additional stereocontrol, results in the for-
mation of an equimolar mixture of two endo diastereomers. To
the best of our knowledge JBIR-22 (3) exists, as a single
diastereomer, so our studies suggest that if a late stage DA reac-
tion is used to prepare JBIR-22 (3) in nature, an asymmetric
catalyst is required, consistent with recent studies on 4.18
To investigate the feasibility of a late stage DA reaction, a
concise synthesis of the precursor 5 was developed. This used
our reported lactone 6, which was prepared in 3 steps from
pyruvate via a N-tert-butylsulfinyl-directed aldol conden-
sation.13,15 Removal of the N-sulfinyl group and diastereo-
selective reduction gave 7 which was trapped with the
phosphonate-containing Meldrum’s acid derivative 8 to
provide 9 (Scheme 2). A one-pot cyclisation and Horner–Wads-
worth–Emmons olefination with known aldehyde 1013,19 gave
the precursor 5 in an eﬃcient 6 steps (34% yield).20 With 5 in
hand, we aimed to investigate if a late-stage IMDA cyclo-
addition was (i) viable21 and (ii) able to establish the required
absolute configuration at the decalin stereogenic centres.
No significant reaction of 5 was observed in toluene when
heated to 130 °C under microwave conditions over 1 hour or in
CDCl3 at 50 °C for 6 days (Table 1, entries 1 & 2). The DA reac-
tion did proceed in toluene at reflux over 6 days but did not go
to completion. However, the Lewis acid BF3·OEt2 catalysed the
reaction of 5 with complete conversion being observed after
12 hours (−78 °C→rt, entry 3). The stereochemical outcome of
this transformation was assessed by UPLC following hydrolysis
of the crude reaction mixture. An authentic mixture of
diastereomers 3a and 3b was used as a standard.22 Analysis
Scheme 1 (A) Proposed biosynthesis of equisetin (1) involving an early
stage enzyme-catalysed Diels–Alder (DA) cycloaddition.4b (B) Proposed
biosynthesis of Lovastatin (2) involving the Diels–Alderase LovB.2b (C)
Two possible biosynthetic routes to JBIR-22 (3). Route A: Early stage DA
cycloaddition which would require enzyme catalysis to control the
stereochemical outcome. Route B: Late stage DA cycloaddition which
could occur spontaneously under substrate control or occur via enzyme
catalysis. For clarity the numbering system used reﬂects that reported
for equisetin (1) in ref. 4d. PKS = polyketide synthase.
Scheme 2 Synthesis of IMDA precursor 5. (a) (i) HCl (4N in dioxane),
THF, 0 °C, 10 minutes. (ii) NaBH3CN, MeOH, 1.5 hours, 0 °C; (b) 8,
MeCN, reﬂux, 3 hours, 79% over 2 steps; (c) (i) tBuOK, THF, 0 °C, 1 hour.
(ii) 10, THF, 0 °C→rt, 12 hours, 85%. For a more detailed discussion of
the conversion of 9 to 5 see Scheme S2.†
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revealed that a ∼1 : 1 mixture of diastereomers 3a and 3b was
formed (no major additional peaks were observed on analysis
of the crude reaction mixture). This demonstrated that whilst
the DA cycloaddition occurred with high endo selectivity,23 no
significant control of the absolute configuration at C11, C2, C3
and C6 was induced by the remote C5′ and C7′ stereocentres4d
(Scheme 1A and C). These results are consistent with the possi-
bility that JBIR-22 (3) could be formed by a catalysed late stage
IMDA reaction which requires an additional source of stereo-
control to deliver the observed absolute stereochemistry.
Further detailed biochemical studies are required to identify if
an enzyme is involved and to validate at what stage the decalin
ring is formed.
Finally, preliminary attempts to enrich for the formation of
either 3a or 3b using an asymmetric catalyst were carried out
(Scheme 3). C2-symmetric metal–ligand complexes have been
reported to catalyse both intermolecular DA and to a lesser
extent IMDA cycloadditions.24–30 These reactions are most
eﬀective when the dienophile is capable of bidentate coordi-
nation to the catalyst as is the case for 5.31 Therefore, 5 was
stirred for 12 hours (−78 °C→rt) in the presence of either of the
bis(oxazoline) metal complexes 11 or 12, or the Cu(II)-sulfinyl
imidoamidine (siam) complex 13. Analysis of the crude reaction
mixture after ester hydrolysis showed that whilst only moderate
control of the 3a : 3b ratio was observed, the use of 12 did result
in the formation of natural 3a in a 3 : 2 ratio compared to 3b
(Table 1, entry 4).32 Further optimisation of reaction conditions
is on-going with the goal of converting 5 exclusively to 3a.
Conclusions
The studies reported here provide access to a mixture of the
structurally complex and biologically interesting JBIR-22 3a
and its diastereomer 3b in an eﬃcient 8 steps. Furthermore,
our results show that a route that involves a late-stage DA
cycloaddition in the biosynthesis of JBIR-22 (3) cannot be
ruled out. This observation is potentially relevant to other
related natural products including equisetin (1) and
Sch210972 (4). Further optimisation to enable the selective for-
mation of either 3a or 3b is on-going. This will also facilitate
access to analogues of JBIR-22 (3) and to other biologically
relevant tetramic acid natural products containing diverse
decalin rings.
Experimental section
Materials and methods
All chemicals and solvents were purchased from Aldrich (UK),
Alfa Aesar, or Acros Organics and used without further purifi-
cation. All reactions involving moisture sensitive reagents were
performed in oven or flame dried glassware under a positive
pressure of nitrogen. Tetrahydrofuran (THF), dichloromethane
(DCM) and hexanes were obtained dry from a solvent purifi-
cation system (MBraun, SPS-800). Anhydrous N,N-dimethyl-
formamide (DMF) was purchased from Aldrich. Thin layer
chromatography (TLC) analysis was performed using glass
plates coated with silica gel (with fluorescent indicator UV254).
Developed plates were air dried and analysed under a UV lamp
(254/365 nm) or by KMnO4 dip staining. Flash chromatography
was performed using silica gel (40–63 μm, Fluorochem).
Fourier Transform infra-red spectra (FT IR) were acquired on a
Shimadzu IRAﬃnity-1 FT spectrophotometer with a Pike
MIRacle™ (solid or thin film). Absorption maxima are
reported in wavenumbers (cm−1). Nuclear magnetic resonance
(NMR) spectra were recorded at room temperature on Bruker
Avance 500 (1H, 499.9 MHz; 13C, 125.7 MHz) and Bruker
Avance 400 (1H, 400.1 MHz; 13C, 100.6 MHz) instruments.
NMR spectra were recorded in deuterated solvents and intern-
ally referenced to the residual solvent peak, chloroform-d
(δC 77.16, δH 7.26 ppm) or acetone-d6 (δC 29.8, δH 2.04 ppm).
Chemical shifts are expressed as δ in units of ppm. 13C NMR
Table 1 A selection of the conditions screened to promote the IMDA
cyclisation of 5
Catalyst/temperature Solvent Time
Selectivity
(3a : 3b)
1 130 °C Toluene 1 ha NR
2 50 °C CDCl3 6 d NR
3 BF3·OEt2 (−78 °C→rt) DCM 12 h 53 : 47b,c
4 Mg-bisoxazoline (12)
(−78 °C→rt)
DCM 12 h 61 : 39b,c,d
aMicrowave reaction. Extended reflux (6 days) in toluene led to partial
conversion (data not shown). b 3a : 3b ratios are an average of 3
samples run in duplicate. c ESI for UPLC traces. d 20 mol% of 12 was
used.
Scheme 3 IMDA cyclisation of 5 followed by hydrolysis to yield
diastereomeric mixture of 3a and 3b. (a) See text and Table 1 for con-
ditions of thermal and Lewis acid catalysed IMDA; (b) NaOH (2 N), EtOH,
110 °C (MW), 20 minutes, (71% for Table 1, entry 3). Crude reaction mix-
tures analysed by 1H NMR and UPLC.
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spectra were recorded using the PENDANT sequence mode.
Data processing was carried out using the MestReNova 8.1.1
NMR program (Mestrelab Research S.L.). Low resolution (LR)
and high resolution (HR) electrospray mass spectral (ES-MS)
analyses were acquired by electrospray ionisation (ESI). Optical
rotations were measured on a polarimeter Perkin-Elmer 341 at
20 °C at a wavelength of λ 589.3 nm in a 1 mL quartz cell
(1 dm length). The concentration is given in g per 100 mL. The
UPLC data was obtained using an Aquity™ UPLC system.
Representative procedure for the Diels–Alder cyclisation
reaction
To a solution of 5 (1.0 eq.) in DCM at −78 °C was added
BF3·Et2O (2.0 eq.) or 20 mol% Cu(II)-bis(oxazoline) complex
(11),29 Mg(II)-bis(oxazoline) complex (12)33 or Cu(II)-siam
complex (13)26 and the reaction was stirred for 1 hour before
slowly warming to room temperature over 11 hours. The reac-
tion was diluted with H2O and extracted with DCM. The
organic layers were combined, washed with brine, dried over
MgSO4, filtered and concentrated in vacuo. Analysis of the
crude reaction mixture by 1H NMR was used to confirm com-
pletion of the reaction. To a solution of the crude ester in
EtOH was added an aqueous solution of NaOH (2 N) and the
reaction was heated to 110 °C under microwave irradiation for
20 minutes. A sample of the reaction mixture was analysed
directly by UPLC. See indicated references for the preparation
of the catalytic complexes.
For experimental details and synthesis of 5, 9, 3a and 3b
see the ESI.†
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